These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10603708)

  • 21. [Investigation of cytomegalovirus seroepidemiology in Antalya with a population-based cross-sectional study and review of related data in Turkey].
    Ataman S; Colak D; Günseren F; Senol Y; Colak T; Aktekin MR; Gültekin M
    Mikrobiyol Bul; 2007 Oct; 41(4):545-55. PubMed ID: 18173073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Leukocyte depletion and infection by cytomegalovirus].
    Mazeron MC
    Transfus Clin Biol; 2000 Jun; 7 Suppl 1():31s-35s. PubMed ID: 10919221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Setting up a CMV negative donor file].
    Yung CH; Chow MP; Hu HY; Tzeng JL; Cheng HI
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1990 Nov; 23(4):312-7. PubMed ID: 1966075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CMV antibody prevalence and seroincidence in plateletpheresis donors.
    Boeke CE; Pauly ME; Hatch-Stock H; Jackson JB
    J Clin Apher; 2008; 23(2):63-5. PubMed ID: 18181166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion.
    Ziemann M; Krueger S; Maier AB; Unmack A; Goerg S; Hennig H
    Transfusion; 2007 Nov; 47(11):1972-83. PubMed ID: 17958525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires].
    Blejer JL; Saguier MC; Salamone HJ; Carreras LA
    Sangre (Barc); 1995 Dec; 40(6):447-51. PubMed ID: 8850226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection of neonates from transfusion-associated AIDS by the use of CMV-seronegative blood before availability of specific serologic tests for HTLV-III (HIV).
    Brady MT; Ng A
    Am J Perinatol; 1987 Oct; 4(4):305-7. PubMed ID: 2820434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Viral screening of organ donors and human cytomegalovirus seroprevalence in the Hungarian population].
    Varga M; Görög D; Kári D; Fazekas J; Sárváry E; Sulyok B; Perner F
    Orv Hetil; 2001 Nov; 142(47):2631-3. PubMed ID: 11778361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections.
    Ziemann M; Heuft HG; Frank K; Kraas S; Görg S; Hennig H
    Transfusion; 2013 May; 53(5):1088-94. PubMed ID: 23320406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of and screening for cytomegalovirus infection in pregnant women.
    Munro SC; Hall B; Whybin LR; Leader L; Robertson P; Maine GT; Rawlinson WD
    J Clin Microbiol; 2005 Sep; 43(9):4713-8. PubMed ID: 16145132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a prescreening blood donor program for prevention of perinatal transfusion-acquired cytomegalovirus (CMV) infection.
    Bhumbra NA; Lewandowski P; Lau P; Sererat M; Satish M; Nankervis GA
    J Perinat Med; 1988; 16(2):127-31. PubMed ID: 2845045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of an enzyme-linked immunoassay with an indirect hemagglutination assay for the detection of antibodies to cytomegalovirus.
    Chairez R; Schleicher JB; Cesario AJ
    J Virol Methods; 1984 Oct; 9(2):153-61. PubMed ID: 6096389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfusion-transmitted cytomegalovirus infections: significance and control.
    Tegtmeier GE
    Vox Sang; 1986; 51 Suppl 1():22-30. PubMed ID: 3017003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroprevalence, transmission, and associated factors of specific antibodies against cytomegalovirus among pregnant women and their infants in a regional study.
    Erfanianahmadpoor M; Nasiri R; Vakili R; Hassannia T
    Saudi Med J; 2014 Apr; 35(4):360-4. PubMed ID: 24749132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients.
    Ziemann M; Juhl D; Görg S; Hennig H
    Transfusion; 2013 Oct; 53(10):2183-9. PubMed ID: 23581526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CMV DNA is rarely detected in healthy blood donors using validated PCR assays.
    Roback JD; Drew WL; Laycock ME; Todd D; Hillyer CD; Busch MP
    Transfusion; 2003 Mar; 43(3):314-21. PubMed ID: 12675715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antibodies to cytomegaloviruses in blood donors].
    Courault K; Lissé I; Richter H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):183-6. PubMed ID: 2475395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placental transfer of naturally acquired, maternal cytomegalovirus antibodies in term and preterm neonates.
    Mussi-Pinhata MM; Pinto PC; Yamamoto AY; Berencsi K; de Souza CB; Andrea M; Duarte G; Jorge SM
    J Med Virol; 2003 Feb; 69(2):232-9. PubMed ID: 12683413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?
    Saghafi H; Qorashi M; Heidari A
    Transplant Proc; 2009 Sep; 41(7):2761-3. PubMed ID: 19765428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.